| Expression pattern: |
UP |
| Associated gene: |
YAP, PD-L1, S100A2 |
| Associated microRNA: |
miR-146b-5p |
| Biological function: |
Confers Gefitinib resistance and malignant behaviors; promotes Gefitinib IC50, cell proliferation, colony formation, tumor growth and immune escape; inhibits apoptosis and cell cycle arrest in Gefitinib-resistant NSCLC. |
| Molecular mechanism: |
circ_0014235 acts through a ceRNA-like mechanism by targeting miR-146b-5p, relieving miR-146b-5p-mediated inhibition of YAP, and subsequently regulating PD-L1 expression. |
| Biological pathway or process: |
drug resistance (promotes); chemoresistance (promotes); proliferation (promotes); apoptosis (inhibits); cell cycle (promotes); immune regulation (promotes); Hippo/YAP (promotes); ceRNA regulation (other) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Transfection; CCK8; Colony Formation Assay; EdU Staining; Cell Cycle Assay; Annexin V/PI Flow Cytometry; Western Blot; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); In Vivo Animal Model; IHC (Immunohistochemistry); Bioinformatics Analysis |
| Clinical significance: |
- |
| Description: |
circ_0014235 is up-regulated in Gefitinib-resistant NSCLC cells and promotes Gefitinib resistance, proliferation, colony formation, tumor growth and immune escape while suppressing apoptosis and cell cycle arrest. Mechanistically, circ_0014235 targets miR-146b-5p to relieve inhibition of YAP and regulate PD-L1 expression, forming a circ_0014235/miR-146b-5p/YAP/PD-L1 pathway. |
| Confidence score: |
0.795 |